We explored combination immunotherapy using the subcutaneous (s.c.)administration of MOF-gated MS cancer vaccines plus intraperitoneal (i.p.)injection of anti-PD-1 Ab (Figs. 5 and 6a, b; Supplementary Figs. 31–33). This evidence concerns the gene PDCD1 and cancer.